Drug Approval | March 28, 2024
Biocon to obtain approval for diabetes drug, Liraglutide in UK
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments
Subscribe To Our Newsletter & Stay Updated
